Literature DB >> 1544335

[Recurrent agranulocytosis after taking calcium dobesilate].

W Kulessa1, E W Becker, P A Berg.   

Abstract

A 64-year-old woman fell ill with generalized pyoderma and fever up to 40 degrees C. White cell count was 600/microliters, with 96% lymphocytes. Granulopoiesis in the bone marrow was markedly diminished. After treatment with cefotaxime, 2 g twice daily for one week, the blood count returned to normal. 8 months later generalized pyoderma, fever and agranulocytosis (white cell count 700/microliters) recurred. Once again the findings improved on ofloxacin 200 mg twice daily for 9 days. On repeat questioning about previous drug intake the patient stated that each time before the onset of the agranulocytosis she had taken calcium dobesilate, 500 mg twice daily for the preceding 15 and 3 weeks, respectively. Thereupon a lymphocyte transformation test was performed which revealed significant stimulation by calcium dobesilate 4, 8 and 14 weeks after the second episode of agranulocytosis. -Allergic side effects of calcium dobesilate have repeatedly been reported, but there has been no previously published report of agranulocytosis induced by this drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544335     DOI: 10.1055/s-2008-1062322

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes.

Authors:  F W Busch; A Tillmann; E W Becker; M Owsianowski; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Calcium dobesilate-induced agranulocytosis.

Authors:  E García Benayas; B García Díaz; G Pérez
Journal:  Pharm World Sci       Date:  1997-10

Review 3.  Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.

Authors:  Hervé Allain; Albert A Ramelet; Elisabeth Polard; Danièle Bentué-Ferrer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.